id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-N-0301-0001,FDA,FDA-2003-N-0301,FDA,Notice,NPH-Notice of Opportunity of Hearing,2003-12-12T05:00:00Z,2003,12,2003-08-05T04:00:00Z,2003-09-09T03:59:59Z,2008-04-12T01:00:02Z,,0,0,0900006480493d43
FDA-2003-N-0301-0004,FDA,FDA-2003-N-0301,GCF-1 (Separation of Functions),Other,SF-Separation of Functions,2003-12-12T05:00:00Z,2003,12,,,2008-04-12T01:00:02Z,,0,0,0900006480493da7
FDA-2003-N-0301-0002,FDA,FDA-2003-N-0301,FDA,Notice,NCR-Notice of Correction,2003-12-12T05:00:00Z,2003,12,2003-08-05T04:00:00Z,2003-11-07T04:59:59Z,2008-04-12T01:00:02Z,,0,0,0900006480493da5
FDA-2003-N-0301-0003,FDA,FDA-2003-N-0301,HFV-1 to Buchanan Ingersoll,Other,LET-Letter,2003-12-12T05:00:00Z,2003,12,,,2011-06-16T18:08:21Z,,0,0,0900006480493da6